From Boardroom Moves to FDA Progress: The Week’s Biggest ASX Swings

Killi Resources (ASX:KLI) led the week with a 226.92% surge after appointing former Fortescue CEO Nev Power as Non-Executive Chair and completing a $1.4m placement. Amplia Therapeutics (ASX:ATX) jumped 117.78% after reporting five complete responses in its pancreatic cancer trial, but much of the early spike faded after trading reopened. Forte Energy (ASX:FEL) was the standout faller, down -28.57%, with the stock reopening lower and then sliding further.

Small-cap leadership was about people and proof

Killi’s move was driven by a simple story: a high-profile chair and new money. Investors often treat a known operator as a signal that a company can raise funds and run a tighter plan. The placement was at a discount, but the buying overwhelmed that concern. Amplia’s rally was about clinical results that are easy to understand. A “complete response” means the cancer could not be detected on scans for those patients at the time measured. That matters in pancreatic cancer because results are usually poor. The pullback after the reopen suggests some traders took quick profits once the initial rush passed.

Medtech ran on approvals, hospital sites and US access

4DMedical (ASX:4DX) rose 46.05% after two concrete steps: CE Mark approval for CT:VQ™ (which allows sales across the EU) and an $83m placement to fund that rollout. Mayo Clinic also started using CT:VQ™ in a 90-day deployment, which investors read as a strong vote from a top hospital. Echo IQ (ASX:EIQ) gained 46.88% after expanding its Mayo Clinic distribution deal for EchoSolv HF, conditional on FDA clearance. In plain terms, the product still needs US approval, but the sales channel is being lined up ahead of time. Lumos Diagnostics (ASX:LDX) ended down slightly at -1.92%, despite a major FDA CLIA waiver for FebriDx®. The waiver matters because it lets the test be used in many more clinics, not just big labs. The muted share move suggests some investors wanted to see sales traction after the regulatory win.

Critical minerals kept winning deals, funding and government attention

Nickel Industries (ASX:NIC) added 1.69% after lifting its 2026 ore sales licence and locking in a 15-year supply deal for minimum volumes. Long contracts matter because they reduce the risk of a plant sitting idle. Syrah Resources (ASX:SYR) fell -8.47% even after announcing a fully underwritten A$104m equity raise and flagging strategic funding proposals from US agencies and AustralianSuper. The fall is common in discounted raisings: existing holders worry their slice gets smaller, and some sell first. Group 6 Metals (ASX:G6M) held flat after extending a tungsten offtake with Traxys valued at an estimated US$1.75b at current prices. An offtake is a customer agreement. It helps sales certainty, but the market often waits to see production volumes before re-rating.

Gold and base metals: drills and spreadsheets moved prices

Exploration names ran on fresh drilling hits and bigger resource numbers. Waratah Minerals (ASX:WTM) climbed 22.32% after reporting more high-grade gold intersections and stepping up drilling with nine rigs. Mount Ridley Mines (ASX:MRD) rose 16.67% after declaring a large inferred heavy rare earth resource with dysprosium and terbium. Manuka Resources (ASX:MKR) slipped -3.03% despite publishing an amended study with an A$805m NPV8 and a plan targeting production in Q2 2026. For early-stage mine restarts, investors often focus less on the headline NPV and more on whether the schedule and assumptions hold when work starts.

Why some stocks fell even on “good” announcements

Weebit Nano (ASX:WBT) dropped -25.54% after raising A$87m at a discount. Extra cash can speed product development, but discounted placements can drag the share price in the short term because new shares come in cheaper. BlinkLab (ASX:BB1) fell -12.35% even with two positive updates: first patient enrolled in its pivotal FDA study, and selection for Morocco’s national early autism screening program. The most likely reason is timing. A pivotal study still takes months, and investors may be waiting for clear revenue from the Morocco program. Synlait Milk (ASX:SM1) was one of the few clear negative reads, after posting an $80.6m half-year loss and announcing asset sales as part of a recovery plan. Even with slightly higher revenue, the loss told the market the factory issues were expensive and not yet fixed.